Menu
Not yet recruiting NCT07289074

Neurokinin A and Matrix Metalloproteinase 9 Levels in Gingival Crevicular Fluid Samples of Teeth With Symptomatic Irreversible Pulpitis With Symptomatic Apical Periodontitis

— Observational Symptomatic Irreversible Pulpitis With Apical Peridontitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Gingival crevicular fluid samples from the symptomatic teeth and the healthy contrlateral teeth.
Who it may be relevant to
Registry conditions: Symptomatic Irreversible Pulpitis With Apical Peridontitis. Basic parameters: 18 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Neurokinin A and Matrix Metalloproteinase 9 Levels in Gingival Crevicular Fluid Samples of Teeth With Symptomatic Irreversible Pulpitis With Symptomatic Apical Periodontitis: A Comparative Cross Sectional Study

Overview

The aim of this study is to investigate the levels Neurokinin A and of Matrix Mtalloproteinase (MMP-9) in gingival crevicular fluid samples (GCF) as potential biomarkers for the diagnosis of symptomatic irreversible pulpitis with symptomatic apical periodontitis and to correlate the level of these diagnostic biomarkers ( Nerokinin A and MMP-9) with the pre-operative pain severity using the Numerical Rating Scale (NRS). This study will utilize a comparative cross-sectional design to assess the levels of Neurokinin A (NKA) and Matrix metalloproteinase-9 (MMP-9) in gingival crevicular fluid (GCF) samples from symptomatic and healthy contralateral teeth with normal pulp.

Detailed description

The study design is Comparative Cross sectional study. The study will be conducted at the Dental hospital of Cairo University with access to patients undergoing treatment for teeth with pulpitis and apical periodontitis.

Interventions

  • Diagnostic test Gingival crevicular fluid samples from the symptomatic teeth and the healthy contrlateral teeth
    The detection of the inflammatory biomarkers levels in the gingival crevicular fluid of the symptomatic teeth is considered an objective,molecular-based and non invasive method for diagnosis.

Primary outcome measures

  • The level of Neurokinin A in gingival crevicular fluid samples of teeth diagnosed with symptomatic irreversible pulpitis with symptomatic apical peridontitis and the contralateral teeth with healthy normal pulp. [Time frame: Pre-operative measurement for Neurokinin A in gingival crevicular fluid samples]
Secondary outcome measures (1)
  • A- The level of MMP-9 in gingival crevicular fluid samples of the symptomatic teeth and the contralateral teeth with normal pulp. B- The pre-operative pain severity in relation with the levels of these diagnostic biomarkers (Nerokinin A and MMP-9). [Time frame: A- Pre-operative measurement for Matrix Metalloproteinase 9 in gingival crevicular fluid samples. B- Pre-operative pain severity assessment to corelate it with the levels of these diagnostic biomarkers (Nerokinin A and MMP-9)..]

Eligibility criteria

Inclusion criteria

  • Adults (aged 18-60) diagnosed with symptomatic irreversible pulpitis with symptomatic apical periodontitis and have healthy contralateral teeth with normal pulp.
  • The involved teeth should have healthy periodontal conditions (Normal periodontal pocket depth, No bleeding on Probing and No mobility).
  • Patients who have not undergone any previous dental treatments in the involved teeth.
  • Signed informed consent.

Exclusion criteria

  • Patients with systemic diseases affecting the immune response (e.g., autoimmune diseases, uncontrolled diabetes).
  • Patients taking medications that can affect the inflammatory markers (e.g., Steroids and Tetracyclins).
  • Smokers.
  • Individuals with periodontal disease unrelated to apical periodontitis.
  • Presence of marginal bone loss.
  • Pregnant women.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

Egypt · 1 center
  • Faculty of Dentistry, Cairo university — Cairo

Identifiers

NCT: NCT07289074 · Hadeer Mostafa -14422022580639

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗